Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 19/20 | 0.61 |
| ▸ | CNR2 | P34972 | 18/20 | 0.61 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3481953 | 0.77 | CNR1 (0.61) | CNR1CNR2 | |
| SCHEMBL3482323 | 0.76 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL3481904 | 0.70 | CNR1 (0.67) | CNR1CNR2 | |
| SCHEMBL3481603 | 0.67 | CNR1 (0.64) | CNR1CNR2 | |
| SCHEMBL13433817 | 0.63 | CNR1 (0.77) | CNR1CNR2 | |
| SCHEMBL3622347 | 0.61 | CNR1 (0.76) | CNR1CNR2EGFRALOX5ADORA3 | |
| SCHEMBL3482312 | 0.61 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL3481895 | 0.61 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL3619248 | 0.61 | CNR1 (0.74) | CNR1CNR2EGFRALOX5ADORA3 | |
| SCHEMBL3624453 | 0.61 | CNR1 (0.64) | CNR1CNR2EGFRALOX5ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063032-A1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2010-03-11 | — | — | US | claimed |
| US-20100063032-A1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2010-03-11 | — | — | US | disclosed |
| US-20100063032-A1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2010-03-11 | — | — | US | disclosed |
| US-20100063032-A1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2010-03-11 | — | — | US | disclosed |
| WO-2008121257-A1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063032-A1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | CNR1, CNR2, FAAH | CNR1 1/4885CNR2 2/4885SLC2A2 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.